PLYX
Polaryx Therapeutics, Inc. Common Stock
1W: -12.9%
1M: +107.5%
YTD: -84.2%
$5.54
-0.11 (-1.95%)
After Hours: $5.46 (-0.08, -1.53%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$260.9M
52W Range2.2-48.91
Volume1,157,820
Avg Volume3,186,315
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAlex Yang
Employees11
SectorHealthcare
IndustryBiotechnology
IPO Date2026-02-02
Websitepolaryx.com
South Tower
Paramus, NJ 07652
US
Paramus, NJ 07652
US
(201) 940-7236
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement for late infantile neuronal ceroid lipofuscinosis (LINCL) and other forms of NCL; PLX-200, a repurposed drug that is used to treat other diseases in adults and children; and PLX-300, a drug isolated from an edible plant that activates PPARa, which enhances production of transcription factor EB. The company was founded in 2014 and is based in Paramus, New Jersey.
Latest News
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
Recent Insider Trades
No insider trades found